Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.

Abstract:

:Tumors of the CNS frequently have devastating consequences in terms of cognitive and motor function, personality and mortality. Despite decades of work, current therapies have done little to alter the course of these deadly diseases. The discovery that chaperones/heat-shock proteins play an important role in tumor biology and immunology have sparked much interest in utilizing these proteins as targets of therapeutics, or as therapeutics themselves, in the treatments of a variety of cancers. Neuro-oncology has only recently taken notice of these entities, and the purpose of this review is to provide a background, an update and a view to the future for the roles of chaperones/heat-shock proteins in the treatment of brain tumors.

authors

Graner MW,Bigner DD

doi

10.1586/14737140.6.5.679

subject

Has Abstract

pub_date

2006-05-01 00:00:00

pages

679-95

issue

5

eissn

1473-7140

issn

1744-8328

journal_volume

6

pub_type

杂志文章,评审
  • Clinical management of borderline ovarian tumors.

    abstract::Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.90

    authors: Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

    更新日期:2010-07-01 00:00:00

  • Advances in the treatment of Waldenström's macroglobulinemia.

    abstract::Waldenström's macroglobulinemia is a distinct disorder characterized by a monoclonal immunoglobulin M paraprotein and morphological evidence of lymphoplasmacytic lymphoma. It is relatively rare, accounting for approximately 2% of all hematological malignancies. The aim of treatment for patients with Waldenström's macr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.3.329

    authors: Johnson SA

    更新日期:2006-03-01 00:00:00

  • Specific challenges in the management of subungual melanoma.

    abstract::Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.216

    authors: De Giorgi V,Saggini A,Grazzini M,Gori A,Rossari S,Scarfì F,Verdelli A,Chimenti S,Lotti T,Massi D

    更新日期:2011-05-01 00:00:00

  • Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

    abstract::This review summarizes the safety of sorafenib, an oral multikinase inhibitor, focusing on the randomized, placebo-controlled, Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) in renal cell carcinoma, which formed the basis of the approval of sorafenib. Similar to other targeted agents, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1193

    authors: Hutson TE

    更新日期:2007-09-01 00:00:00

  • Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.

    abstract::As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.104

    authors: Batus M,Fidler MJ,Bonomi PD

    更新日期:2010-10-01 00:00:00

  • Is axillary dissection needed in node-positive breast cancer?

    abstract::The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.8.2.195

    authors: Greenberg CC,Bafford AC,Golshan M

    更新日期:2008-02-01 00:00:00

  • Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.

    abstract::With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.3.267

    authors: Dixon JM

    更新日期:2002-06-01 00:00:00

  • Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.

    abstract::The European Society for Medical Oncology (ESMO) recommendations on the management of gastrointestinal stromal tumor (GIST) have recently been updated. Imatinib 400 mg/day remains the standard first-line treatment for patients with metastatic GIST. Mutational analysis has received a strong recommendation for diagnosti...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.34

    authors: Blay JY,Reichardt P

    更新日期:2009-06-01 00:00:00

  • Venous thromboembolism and malignancy.

    abstract::The association between venous thromboembolism (VTE) and malignancy was first recognized more than 135 years ago. Since then, a markedly increased incidence of VTE has been found in patients with malignant disease. Numerous clinical studies have demonstrated that malignancy or its treatment are major risk factors for ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.2.303

    authors: Gao S,Escalante C

    更新日期:2004-04-01 00:00:00

  • Lenalidomide in multiple myeloma.

    abstract::Treatment options for patients have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Owing to the promising activity seen with lenalidomide in the relapsed/refractory setting, its use has now expanded to induction and maintenance therapy. ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.123

    authors: Sirohi B,Powles R

    更新日期:2009-11-01 00:00:00

  • Squamous cell carcinoma of the vulva: a review of present management and future considerations.

    abstract:INTRODUCTION:Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly en...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1538797

    authors: Buchanan T,Mutch D

    更新日期:2019-01-01 00:00:00

  • Androgen receptor: role and novel therapeutic prospects in prostate cancer.

    abstract::Androgen receptor (AR) signaling is necessary for the development of prostate cancer. Androgen-deprivation therapy (ADT) for prostate cancer was described over 50 years ago and ADT remains the mainstay of systemic therapy. AR signaling remains intact as the disease evolves to castration-resistant prostate cancer (CRPC...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.9.1495

    authors: Taplin ME

    更新日期:2008-09-01 00:00:00

  • The evolving role of receptors as predictive biomarkers for metastatic breast cancer.

    abstract:INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1552138

    authors: Martínez-Pérez C,Turnbull AK,Dixon JM

    更新日期:2019-02-01 00:00:00

  • Breast cancer metastasis progression as revealed by intravital videomicroscopy.

    abstract::Metastasis is the spread of cells from a primary tumor to a distant site, where they arrest and grow to form a secondary tumor. Conventional metastasis models have focused primarily on analysis of end point tumor formation following inoculation with tumor cells. This approach can be used to measure the metastatic pote...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.9.1271

    authors: MacDonald IC,Chambers AF

    更新日期:2006-09-01 00:00:00

  • Chemoprevention of prostate cancer.

    abstract::Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.2.203

    authors: Ward JF,Blute ML

    更新日期:2003-04-01 00:00:00

  • The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.

    abstract::Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1586/era.11.34

    authors: Metro G,Crinò L

    更新日期:2011-05-01 00:00:00

  • The multidisciplinary management of giant cell tumor of bone.

    abstract::Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in a small proportion of patients, metastatic disease can develop. Surgery is the mainstay of management for extremity-based lesions. For tumors located in challenging anatomical locations such as the sacrum and spine...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.901891

    authors: Ng VY,Davidson DJ,Kim EY,Pollack SM,Conrad Iii EU,Jones RL

    更新日期:2014-07-01 00:00:00

  • ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

    abstract::Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer. Optimizing the management of frequent crizotinib-related adverse events is crucial to ensure its continuous administration and reprodu...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.986103

    authors: Girard N,Audigier-Valette C,Cortot AB,Mennecier B,Debieuvre D,Planchard D,Zalcman G,Moro-Sibilot D,Cadranel J,Barlési F

    更新日期:2015-02-01 00:00:00

  • From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.

    abstract::One of the most prominent pathways explored in the area of targeted therapy is the PI3K/Akt/mTOR pathway, which plays a central role in cell survival and proliferation. Deregulation of this pathway has been implicated in the promotion of cancer cell growth and survival. Inhibition of several steps of this pathway has ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.131

    authors: Georgakis GV,Younes A

    更新日期:2006-01-01 00:00:00

  • Clinical implications of lung neuroendocrine neoplasm classification.

    abstract:INTRODUCTION:Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell carcinoma and large-cell NE carcinoma. This classification is the current basis for orienting the daily practi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1862654

    authors: Metovic J,Barella M,Harari S,Pattini L,Albini A,Sonzogni A,Veronesi G,Papotti M,Pelosi G

    更新日期:2020-12-24 00:00:00

  • Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract.

    abstract:INTRODUCTION:To date, all efforts to fight gastrointestinal cancer, regardless of its origin and entity, have resulted in complex therapeutic regimens involving a combination of systemic therapy, radiation therapy and surgery. It is generally accepted across all disciplines that not one, but the combination and the pro...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1868991

    authors: Neumann PA,Berlet MW,Friess H

    更新日期:2021-01-08 00:00:00

  • Role of FDG-PET in the diagnosis and management of lung cancer.

    abstract::Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.4.561

    authors: Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

    更新日期:2004-08-01 00:00:00

  • Oncogenomics: prospects for the future.

    abstract::Genomics has generated a wealth of data that is now being used to identify additional molecular alterations associated with cancer development. Mapping these alterations in the cancer genome is a critical first step in dissecting oncological pathways. There are two ways in which cancer research has changed in recent y...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.6.891

    authors: Sakatani T,Onyango P

    更新日期:2003-12-01 00:00:00

  • Stem cell transplantation in Hodgkin lymphoma.

    abstract::Hematopoietic stem cell transplantation is an effective treatment for patients with relapsed or refractory Hodgkin lymphoma. Treatment outcome is better among patients who demonstrate sensitivity to salvage chemotherapy. Approximately half of the patients undergoing autologous stem cell transplantation will be cured a...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.3.297

    authors: Murphy F,Sirohi B,Cunningham D

    更新日期:2007-03-01 00:00:00

  • Management of residual masses in testicular germ cell tumors.

    abstract:INTRODUCTION:About 50% of all patients with advanced testicular cancer demonstrate residual retroperitoneal or extraretroperitoneal masses. About two thirds of the masses harbour necrosis/fibrosis only whereas as about 10% and 40% harbour vital cancer or teratoma. Appropriate therapy will result in a high cure rate if ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1580146

    authors: Heidenreich A,Paffenholz P,Nestler T,Pfister D

    更新日期:2019-04-01 00:00:00

  • Statistical approaches for evaluating body composition markers in clinical cancer research.

    abstract:INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1298446

    authors: Bayar MA,Antoun S,Lanoy E

    更新日期:2017-04-01 00:00:00

  • Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?

    abstract:INTRODUCTION:: Renal cell carcinoma is no longer considered a monolithic disease, but a group of different entities exhibiting unique molecular alterations requiring a tailored systemic approach. One of the remaining challenges is the identification of the best candidate for a particular therapeutic regimen. AREAS COV...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1878882

    authors: González J,Gaynor JJ,Ciancio G

    更新日期:2021-01-29 00:00:00

  • Chemoprevention of lung cancer: concepts and strategies.

    abstract::Lung cancer develops in a stepwise fashion, with an accumulation of molecular alterations progressing through preinvasive steps to invasive disease. This progression could be arrested or reversed through pharmacologic treatments, which are known as cancer chemoprevention. Preclinical and clinical findings relating to ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.3.549

    authors: Cohen V,Khuri FR

    更新日期:2005-06-01 00:00:00

  • Oncolytic viruses: a novel form of immunotherapy.

    abstract::Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.10.1581

    authors: Prestwich RJ,Harrington KJ,Pandha HS,Vile RG,Melcher AA,Errington F

    更新日期:2008-10-01 00:00:00

  • Minimally invasive cystectomy approaches in the treatment of bladder cancer.

    abstract::Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.52

    authors: Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

    更新日期:2012-06-01 00:00:00